These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 31122263)

  • 21. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Eiring AM; Khorashad JS; Anderson DJ; Yu F; Redwine HM; Mason CC; Reynolds KR; Clair PM; Gantz KC; Zhang TY; Pomicter AD; Kraft IL; Bowler AD; Johnson K; Partlin MM; O'Hare T; Deininger MW
    Leukemia; 2015 Dec; 29(12):2328-37. PubMed ID: 26202934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
    Mancini M; Leo E; Aluigi M; Marcozzi C; Borsi E; Barbieri E; Santucci MA
    Leuk Res; 2012 Aug; 36(8):1028-34. PubMed ID: 22521726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z
    Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S
    Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
    Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
    Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
    Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
    Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
    Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.